University of Magdeburg
Welcome,         Profile    Billing    Logout  
 13 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ricke, Jens
DEMAND, NCT04224636: Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab

Recruiting
2
106
Europe
Atezolizumab Injection, Bevacizumab Injection, Chemoembolisation (TACE)
Ludwig-Maximilians - University of Munich
Hepatocellular Carcinoma Non-resectable
03/25
03/25
NCT04238637 / 2018-004778-81: Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Recruiting
2
50
Europe
Durvalumab, Other Name: MEDI4736, Tremelimumab, Study treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, AstraZeneca
Intrahepatic Cholangiocarcinoma
12/25
12/25
HOMIE-166, NCT05451862: Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.

Recruiting
2
73
Europe
Holmium-166 treatment, QuiremSpheresTM Holmium-166 Microspheres, Holmium-166 work-up, QuiremScoutTM Holmium-166 Microspheres
Terumo Europe N.V.
Hepatocellular Carcinoma
01/31
01/31
Koenigsmann, Michael
NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients

Active, not recruiting
3
702
Europe
Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin
Prof. Dr. med. Claus Rödel
Rectal Cancer Stage III
09/23
09/28
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
CLL-Frail, NCT04883749: Efficacy of Acalabrutinib in Very Old or Frail Patients with Treatment-naïve or Relapsed/Refractory CLL

Active, not recruiting
2
53
Europe
Acalabrutinib, Calquence, ACP-196
German CLL Study Group
Chronic Lymphoid Leukemia
05/25
05/25
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Completed
N/A
499
Europe
iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG
Advanced Solid Tumors or Hematologic Malignancies
06/23
06/23
Malfertheiner, Peter
Hp-EuReg, NCT02328131: European Registry on the Management of Helicobacter Pylori Infection

Recruiting
N/A
10000
Europe, RoW
Javier P. Gisbert
H. Pylori Infection
12/34
12/34
Schostak, Martin
PEGASUS, NCT02799706: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer

Active, not recruiting
3
885
Europe
Degarelix, approved GnRH agonist, Radiotherapy
European Organisation for Research and Treatment of Cancer - EORTC
Prostate Cancer
08/23
06/26
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Recruiting
3
250
Europe
Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel
Jena University Hospital, Bayer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
07/25
01/27
OPTIMUM, NCT05220501: Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI

Completed
N/A
804
Europe, Canada, US
Micro-US Targeted Biopsy, MRI Targeted Biopsy
Sunnybrook Health Sciences Centre, Exact Imaging
Prostate Cancer
09/24
11/24
3DPN, NCT06056505: Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy

Recruiting
N/A
370
Europe
partial kidney nephrectomy, DaVinci Robot, Innersight 3D software
University of Leipzig
Kidney Tumor
03/26
09/26

Download Options